Mayo Clinic Laboratories offers innovative testing solutions for the early detection of Alzheimer's disease. Our evaluations, which use CSF biomarkers to achieve a high concordance with an amyloid positron emission tomography (PET) scan, deliver faster results and provide new hope for correctly diagnosing and managing Alzheimer's disease along with other dementias. Learn more about our Alzheimer’s disease testing through the resources below.
Digital Resources
FDA-approved test expands options for Alzheimer's disease [Test in Focus]
Specialty Webinar: Role of CSF in Alzheimer’s Disease
Printable Documents
Neurology Test Requisition Form
Neurodegenerative Disease Flyer